Although further development is clearly needed, CD19-CAR-T-EVs have already been used to target B-cells in acute lymphocytic leukemia [94]; the transfer of this technology to CLL would be of great interest. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.